Developer docs
API playgroundTry for free, no card

Search company profiles

Mira Pharmaceuticals

Full company profile

uuid0000da7

Namestring
Mira Pharmaceuticals
Legal namestring
MIRA Pharmaceuticals, Inc.
Company typeenum
Public
Founded yearint
2020
Descriptiontext

Mira Pharmaceuticals, Inc. (NASDAQ: MIRA) is a clinical-stage pharmaceutical company incorporated in September 2020 and headquartered in Miami, Florida, developing novel oral therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The company operates with a headcount of 1-10 employees and has not yet generated revenue from product sales. Its pipeline consists of three distinct oral drug candidates: Ketamir-2, a low-affinity NMDA receptor antagonist and ketamine analog engineered for oral bioavailability and improved blood-brain barrier penetration (targeting neuropathic pain, chemotherapy-induced peripheral neuropathy (CIPN), treatment-resistant depression, MDD with suicidal ideation, and PTSD); MIRA-55, a non-psychotropic cannabinoid analog designed for selective CB2 activation with minimized CB1 binding (targeting anxiety, cognitive decline associated with early-stage dementia, and inflammatory pain); and SKNY-1, a multi-pathway endocannabinoid modulator combining biased CB1 antagonism, CB2 partial agonism, and mild MAO-B inhibition (targeting obesity and nicotine addiction, acquired through the September 2025 SKNY Pharmaceuticals acquisition).

The company's underlying technology is proprietary medicinal chemistry rather than a software platform: each candidate is a patent-pending novel molecular entity positioned against receptor targets (NMDA, CB1/CB2, MAO-B) where existing therapies have meaningful limitations such as opioid risk, sedation, addiction, or injection-only administration. Mira has secured regulatory advantages including DEA determination that both Ketamir-2 and MIRA-55 are not controlled substances, and FDA IND clearance for Ketamir-2 in neuropathic pain. Preclinical data points to 112% greater efficacy than pregabalin and 100% reversal of nerve-ligation neuropathic pain for Ketamir-2, morphine-comparable anti-inflammatory efficacy for oral MIRA-55, and up to 30% weight loss with muscle preservation for SKNY-1.

Mira's business model is pre-commercial pharmaceutical development: revenue is expected to come from product sales upon FDA approval, with future distribution planned through traditional pharmaceutical wholesale and specialty pharmacy channels. The company currently monetizes only through capital markets activity, having been valued at approximately $68.26 million as of December 2025 with a stock price of $1.63. Customer segments are defined by indication (CIPN patients, neuropathic pain patients, anxiety and cognitive decline patients, obesity and smoking cessation patients, inflammatory pain patients) rather than enterprise buyers, and the company is currently preparing for Phase 2a clinical trials rather than commercial launch. Operating geographies served are the USA, Canada, and Mexico, with clinical operations extending to Israel and the Netherlands.

Short descriptiontext

Mira Pharmaceuticals is a clinical-stage pharmaceutical company developing three novel oral drug candidates — Ketamir-2 (NMDA modulator for neuropathic pain), MIRA-55 (cannabinoid analog for anxiety and pain), and SKNY-1 (endocannabinoid modulator for obesity and addiction) — targeting large unmet needs in neurologic, neuropsychiatric, and metabolic disorders, with no product revenue yet.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMiami, United States
HQ citystring
Miami
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage pharmaceuticals, oral neuropathic pain drugs, ketamine analog therapeutics, cannabinoid analog pharmaceuticals, endocannabinoid system modulators
Industry3 codes
PRIMARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medicinal and Botanical Manufacturing325411
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Clinical-Stage Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Drug Development and Commercialization
TypeOne Time License
Description

Mira Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The company has not yet generated revenue from product sales as all drug candidates are in preclinical or clinical development stages. Future revenue will come from product sales upon FDA approval.

mirapharmaceuticals.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Mira Pharmaceuticals is a clinical-stage pharmaceutical company developing and commercializing novel oral therapeutics for neurologic, neuropsychiatric, and metabolic disorders. Its pipeline consists of three proprietary drug candidates: Ketamir-2 (an oral NMDA receptor modulator/ketamine analog for neuropathic pain and CIPN), MIRA-55 (a non-psychotropic cannabinoid analog for anxiety and inflammatory pain), and SKNY-1 (an endocannabinoid modulator for obesity and nicotine addiction). All three candidates have received DEA determination as non-controlled substances and are progressing through preclinical and Phase 1/2a clinical development toward potential FDA approval and commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Ketamir-2 achieved 60% greater efficacy than gabapentin and 112% greater than pregabalin in preclinical neuropathic pain models
+4 more records
Product overview1 text field

Mira Pharmaceuticals is a clinical-stage pharmaceutical company developing a portfolio of novel oral therapeutics targeting neurologic, neuropsychiatric, and metabolic disorders. The company's pipeline consists of three distinct drug candidates: Ketamir-2 (an NMDA receptor modulator for neuropathic pain and central nervous system disorders), MIRA-55 (a cannabinoid analog for anxiety and cognitive decline), and SKNY-1 (an endocannabinoid modulator for obesity and addiction). All three candidates have received DEA determination as non-controlled substances, supporting their development as non-scheduled therapeutic options.

Product and service3 records
1Ketamir-2
CategoryCore Product - Neuropathic Pain Therapeutics
Description

A novel oral NMDA receptor modulator (ketamine analog) being developed for the treatment of neuropathic pain, chemotherapy-induced peripheral neuropathy (CIPN), treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. The drug has received DEA determination as a non-controlled substance and is currently advancing through Phase 2a clinical trials.

2MIRA-55
CategoryCore Product - Cannabinoid Analog Therapeutics
Description

A novel oral pharmaceutical marijuana analog targeting cannabinoid receptors CB1 and CB2, being developed for anxiety, cognitive decline associated with early-stage dementia, and chronic inflammatory pain. The compound is engineered to provide therapeutic benefits without the psychotropic side effects of THC, with DEA determination as a non-controlled substance.

3SKNY-1
CategoryCore Product - Endocannabinoid Modulator Therapeutics
Description

An oral drug candidate targeting the endocannabinoid system for the treatment of obesity and nicotine addiction. The compound utilizes a multi-pathway approach including biased CB1 antagonism, CB2 partial agonism, and mild MAO-B inhibition, designed to avoid CNS side effects seen with earlier CB1-targeting drugs.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Recipharm
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Recipharm provides critical manufacturing and development support for Mira Pharmaceuticals' drug development programs including GMP preparation for Telomir-1 and Ketamir-2 Phase 1 SAD testing. The partnership supports manufacturing and development advances across clinical programs.

news.cision.com
2Pharmaseed
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research partner conducting preclinical behavioral assays and studies for Mira-55 including validated behavioral tests at doses of 10, 30, and 100 mg/kg oral administration. Partnership enables testing for sedation, catalepsy, motor impairment, and anxiety-like effects.

pharmiweb.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration on spray-dry based granulation of Ketamir-2 in capsules for clinical studies, optimizing formulation for improved oral bioavailability and patient convenience. Drug product development partnership for novel oral ketamine analog capsules.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Selected as clinical trial site in Leiden, The Netherlands for Phase I/IIa trials. Utilizes proprietary PainCart technology for measuring pain response, allowing early efficacy assessment in healthy subjects. Trial design enables robust early proof-of-concept data.

5SKNY Pharmaceuticals
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Acquisition completed adding SKNY-1 drug candidate to pipeline. Transaction included $5 million capital infusion and brought obesity and smoking cessation drug candidate into MIRA's portfolio. Represents transformative pipeline expansion.

mirapharmaceuticals.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage pharmaceutical company developing cannabinoid-derived therapeutics for inflammatory and fibrotic diseases. Comparable mechanism class and clinical-development stage to MIRA's endocannabinoid modulators.

TypeEmerging player
Description

Clinical-stage gene therapy company developing CNS-targeted therapeutics for neurological diseases. Comparable clinical-stage risk profile and small-cap public-company dynamics to MIRA.

TypeBroad incumbent
Description

Commercial-stage CNS biopharmaceutical company with approved products in major depressive disorder and migraine. Overlaps with MIRA's CNS/neuropathic pain focus and represents the scaled-up commercial trajectory MIRA is pursuing.

TypeDirect peer
Description

Clinical-stage specialty pharmaceutical company developing transdermal cannabinoid therapeutics for neuropsychiatric conditions including Fragile X syndrome and epilepsy. Overlaps with MIRA's cannabinoid analog approach.

TypeDirect peer
Description

Clinical-stage mental health care company developing psilocybin-based therapies for treatment-resistant depression. Comparable to MIRA's strategy of repurposing controlled-substance-class chemistry into differentiated, mainstream-positioned therapeutics.

TypeBroad incumbent
Description

CNS-focused biopharmaceutical company with FDA-approved therapy for postpartum depression and a pipeline in major depressive disorder. Comparable regulatory and clinical-development pathway for novel neuro-active compounds.

TypeEmerging player
Description

Specialty pharmaceutical company focused on ketamine-based therapeutics for neurological and mental health disorders. Closely comparable to MIRA's Ketamir-2 program targeting NMDA receptor modulation.

8Atai Life Sciences
TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing psychedelic and cannabinoid-derived therapeutics for mental health indications. Closely comparable to MIRA's MIRA-55 strategy of engineering non-psychotropic cannabinoid analogs.

TypeDirect peer
Description

Clinical-stage CNS-focused pharmaceutical company developing therapeutics for pain, PTSD, depression, and fibromyalgia. Direct comparable to MIRA's Ketamir-2 program targeting neuropathic pain and CNS indications.

10Tetra Bio-Pharma
TypeDirect peer
Description

Clinical-stage cannabinoid-derived pharmaceutical company developing novel treatments for pain and inflammatory conditions. Direct overlap with MIRA's MIRA-55 program targeting chronic inflammatory pain.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mira Pharmaceuticals

Clinical-Stage Pharmaceuticalsmirapharmaceuticals.com

Mira Pharmaceuticals is a clinical-stage pharmaceutical company developing three novel oral drug candidates — Ketamir-2 (NMDA modulator for neuropathic pain), MIRA-55 (cannabinoid analog for anxiety and pain), and SKNY-1 (endocannabinoid modulator for obesity and addiction) — targeting large unmet needs in neurologic, neuropsychiatric, and metabolic disorders, with no product revenue yet.

What Mira Pharmaceuticals does

Mira Pharmaceuticals, Inc. (NASDAQ: MIRA) is a clinical-stage pharmaceutical company incorporated in September 2020 and headquartered in Miami, Florida, developing novel oral therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The company operates with a headcount of 1-10 employees and has not yet generated revenue from product sales. Its pipeline consists of three distinct oral drug candidates: Ketamir-2, a low-affinity NMDA receptor antagonist and ketamine analog engineered for oral bioavailability and improved blood-brain barrier penetration (targeting neuropathic pain, chemotherapy-induced peripheral neuropathy (CIPN), treatment-resistant depression, MDD with suicidal ideation, and PTSD); MIRA-55, a non-psychotropic cannabinoid analog designed for selective CB2 activation with minimized CB1 binding (targeting anxiety, cognitive decline associated with early-stage dementia, and inflammatory pain); and SKNY-1, a multi-pathway endocannabinoid modulator combining biased CB1 antagonism, CB2 partial agonism, and mild MAO-B inhibition (targeting obesity and nicotine addiction, acquired through the September 2025 SKNY Pharmaceuticals acquisition).

The company's underlying technology is proprietary medicinal chemistry rather than a software platform: each candidate is a patent-pending novel molecular entity positioned against receptor targets (NMDA, CB1/CB2, MAO-B) where existing therapies have meaningful limitations such as opioid risk, sedation, addiction, or injection-only administration. Mira has secured regulatory advantages including DEA determination that both Ketamir-2 and MIRA-55 are not controlled substances, and FDA IND clearance for Ketamir-2 in neuropathic pain. Preclinical data points to 112% greater efficacy than pregabalin and 100% reversal of nerve-ligation neuropathic pain for Ketamir-2, morphine-comparable anti-inflammatory efficacy for oral MIRA-55, and up to 30% weight loss with muscle preservation for SKNY-1.

Mira's business model is pre-commercial pharmaceutical development: revenue is expected to come from product sales upon FDA approval, with future distribution planned through traditional pharmaceutical wholesale and specialty pharmacy channels. The company currently monetizes only through capital markets activity, having been valued at approximately $68.26 million as of December 2025 with a stock price of $1.63. Customer segments are defined by indication (CIPN patients, neuropathic pain patients, anxiety and cognitive decline patients, obesity and smoking cessation patients, inflammatory pain patients) rather than enterprise buyers, and the company is currently preparing for Phase 2a clinical trials rather than commercial launch. Operating geographies served are the USA, Canada, and Mexico, with clinical operations extending to Israel and the Netherlands.

Mira Pharmaceuticals firmographics

Firmographics
Name
Mira Pharmaceuticals
Legal name
MIRA Pharmaceuticals, Inc.
Website
https://mirapharmaceuticals.com
Company type
Public
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Mira Pharmaceuticals is a clinical-stage pharmaceutical company developing three novel oral drug candidates — Ketamir-2 (NMDA modulator for neuropathic pain), MIRA-55 (cannabinoid analog for anxiety and pain), and SKNY-1 (endocannabinoid modulator for obesity and addiction) — targeting large unmet needs in neurologic, neuropsychiatric, and metabolic disorders, with no product revenue yet.
Ownership category
akta.pro rank

Mira Pharmaceuticals industry classification

Industry
Product category
Clinical-Stage Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medicinal and Botanical Manufacturing (325411)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Clinical-stage pharmaceuticals
  • Oral neuropathic pain drugs
  • Ketamine analog therapeutics
  • Cannabinoid analog pharmaceuticals
  • Endocannabinoid system modulators

Where Mira Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Miami
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Mira Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Drug Development and Commercialization: Mira Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The company has not yet generated revenue from product sales as all drug candidates are in preclinical or clinical development stages. Future revenue will come from product sales upon FDA approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Mira Pharmaceuticals product offering

Product offering

Core offering

Mira Pharmaceuticals is a clinical-stage pharmaceutical company developing and commercializing novel oral therapeutics for neurologic, neuropsychiatric, and metabolic disorders. Its pipeline consists of three proprietary drug candidates: Ketamir-2 (an oral NMDA receptor modulator/ketamine analog for neuropathic pain and CIPN), MIRA-55 (a non-psychotropic cannabinoid analog for anxiety and inflammatory pain), and SKNY-1 (an endocannabinoid modulator for obesity and nicotine addiction). All three candidates have received DEA determination as non-controlled substances and are progressing through preclinical and Phase 1/2a clinical development toward potential FDA approval and commercialization.

Product overview

Mira Pharmaceuticals is a clinical-stage pharmaceutical company developing a portfolio of novel oral therapeutics targeting neurologic, neuropsychiatric, and metabolic disorders. The company's pipeline consists of three distinct drug candidates: Ketamir-2 (an NMDA receptor modulator for neuropathic pain and central nervous system disorders), MIRA-55 (a cannabinoid analog for anxiety and cognitive decline), and SKNY-1 (an endocannabinoid modulator for obesity and addiction). All three candidates have received DEA determination as non-controlled substances, supporting their development as non-scheduled therapeutic options.

Differentiator

Problem solved

Functional benefit

Products and services

  • Ketamir-2 A novel oral NMDA receptor modulator (ketamine analog) being developed for the treatment of neuropathic pain, chemotherapy-induced peripheral neuropathy (CIPN), treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. The drug has received DEA determination as a non-controlled substance and is currently advancing through Phase 2a clinical trials.
  • MIRA-55 A novel oral pharmaceutical marijuana analog targeting cannabinoid receptors CB1 and CB2, being developed for anxiety, cognitive decline associated with early-stage dementia, and chronic inflammatory pain. The compound is engineered to provide therapeutic benefits without the psychotropic side effects of THC, with DEA determination as a non-controlled substance.
  • SKNY-1 An oral drug candidate targeting the endocannabinoid system for the treatment of obesity and nicotine addiction. The compound utilizes a multi-pathway approach including biased CB1 antagonism, CB2 partial agonism, and mild MAO-B inhibition, designed to avoid CNS side effects seen with earlier CB1-targeting drugs.

Quantifiable outcome

  • Ketamir-2 achieved 60% greater efficacy than gabapentin and 112% greater than pregabalin in preclinical neuropathic pain models
  • +4 more outcomes

Companies that use Mira Pharmaceuticals

Customer profile

Segments5 records

Ideal customer profiles2 records

Mira Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Mira Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • RecipharmcoreImplementation/ SI/ Consulting PartnerRecipharm provides critical manufacturing and development support for Mira Pharmaceuticals' drug development programs including GMP preparation for Telomir-1 and Ketamir-2 Phase 1 SAD testing. The partnership supports manufacturing and development advances across clinical programs.
  • PharmaseedcoreStrategic or Co-development PartnerResearch partner conducting preclinical behavioral assays and studies for Mira-55 including validated behavioral tests at doses of 10, 30, and 100 mg/kg oral administration. Partnership enables testing for sedation, catalepsy, motor impairment, and anxiety-like effects.
  • FormulexcoreStrategic or Co-development PartnerCollaboration on spray-dry based granulation of Ketamir-2 in capsules for clinical studies, optimizing formulation for improved oral bioavailability and patient convenience. Drug product development partnership for novel oral ketamine analog capsules.
  • Centre for Human Drug Research (CHDR)coreStrategic or Co-development PartnerSelected as clinical trial site in Leiden, The Netherlands for Phase I/IIa trials. Utilizes proprietary PainCart technology for measuring pain response, allowing early efficacy assessment in healthy subjects. Trial design enables robust early proof-of-concept data.
  • SKNY PharmaceuticalscoreStrategic or Co-development PartnerAcquisition completed adding SKNY-1 drug candidate to pipeline. Transaction included $5 million capital infusion and brought obesity and smoking cessation drug candidate into MIRA's portfolio. Represents transformative pipeline expansion.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Mira Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Corbus Pharmaceuticals: Clinical-stage pharmaceutical company developing cannabinoid-derived therapeutics for inflammatory and fibrotic diseases. Comparable mechanism class and clinical-development stage to MIRA's endocannabinoid modulators.
  • Zynerba Pharmaceuticals: Clinical-stage specialty pharmaceutical company developing transdermal cannabinoid therapeutics for neuropsychiatric conditions including Fragile X syndrome and epilepsy. Overlaps with MIRA's cannabinoid analog approach.
  • Compass Pathways: Clinical-stage mental health care company developing psilocybin-based therapies for treatment-resistant depression. Comparable to MIRA's strategy of repurposing controlled-substance-class chemistry into differentiated, mainstream-positioned therapeutics.
  • Atai Life Sciences: Clinical-stage biopharmaceutical company developing psychedelic and cannabinoid-derived therapeutics for mental health indications. Closely comparable to MIRA's MIRA-55 strategy of engineering non-psychotropic cannabinoid analogs.
  • Tonix Pharmaceuticals: Clinical-stage CNS-focused pharmaceutical company developing therapeutics for pain, PTSD, depression, and fibromyalgia. Direct comparable to MIRA's Ketamir-2 program targeting neuropathic pain and CNS indications.
  • Tetra Bio-Pharma: Clinical-stage cannabinoid-derived pharmaceutical company developing novel treatments for pain and inflammatory conditions. Direct overlap with MIRA's MIRA-55 program targeting chronic inflammatory pain.

Emerging players

  • Voyager Therapeutics: Clinical-stage gene therapy company developing CNS-targeted therapeutics for neurological diseases. Comparable clinical-stage risk profile and small-cap public-company dynamics to MIRA.
  • PharmaTher: Specialty pharmaceutical company focused on ketamine-based therapeutics for neurological and mental health disorders. Closely comparable to MIRA's Ketamir-2 program targeting NMDA receptor modulation.

Broad incumbents

  • Axsome Therapeutics: Commercial-stage CNS biopharmaceutical company with approved products in major depressive disorder and migraine. Overlaps with MIRA's CNS/neuropathic pain focus and represents the scaled-up commercial trajectory MIRA is pursuing.
  • Sage Therapeutics: CNS-focused biopharmaceutical company with FDA-approved therapy for postpartum depression and a pipeline in major depressive disorder. Comparable regulatory and clinical-development pathway for novel neuro-active compounds.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Mira Pharmaceuticals social profiles

Digital presence

Mira Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mira Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles4 records

Mira Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Mira Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mira Pharmaceuticals M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mira Pharmaceuticals

What does Mira Pharmaceuticals do?

Mira Pharmaceuticals is a clinical-stage pharmaceutical company developing and commercializing novel oral therapeutics for neurologic, neuropsychiatric, and metabolic disorders. Its pipeline consists of three proprietary drug candidates: Ketamir-2 (an oral NMDA receptor modulator/ketamine analog for neuropathic pain and CIPN), MIRA-55 (a non-psychotropic cannabinoid analog for anxiety and inflammatory pain), and SKNY-1 (an endocannabinoid modulator for obesity and nicotine addiction). All three candidates have received DEA determination as non-controlled substances and are progressing through preclinical and Phase 1/2a clinical development toward potential FDA approval and commercialization.

Is Mira Pharmaceuticals a public or private company?

Mira Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Mira Pharmaceuticals founded?

Mira Pharmaceuticals was founded in 2020. It employs 1 to 10 people.

Where is Mira Pharmaceuticals based?

Mira Pharmaceuticals is headquartered in Miami, United States, in the North America region.

How does Mira Pharmaceuticals make money?

One revenue line is on record: pharmaceutical Drug Development and Commercialization.

Who are Mira Pharmaceuticals's main competitors?

Direct peers on record are Corbus Pharmaceuticals, Zynerba Pharmaceuticals, Compass Pathways, Atai Life Sciences, Tonix Pharmaceuticals and Tetra Bio-Pharma. Emerging players are Voyager Therapeutics and PharmaTher. Broad incumbents are Axsome Therapeutics and Sage Therapeutics.

Does Mira Pharmaceuticals have an API?

No public API is recorded for Mira Pharmaceuticals.

What industry is Mira Pharmaceuticals in?

Mira Pharmaceuticals's product category is Clinical-Stage Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAN, Pain Management & Anesthesiology Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewMIRA Pharmaceuticals (MIRA) Reports 680-Fold Mu and 540-Fold Kappa Separation for MIRA-55MIRA Pharmaceuticals reported approximately 680-fold separation from mu opioid receptors and 540-fold from kappa opioid receptors for its preclinical candidate MIRA-55. The company targets an IND submission in the first half of 2027, with no substantial COX-1 or COX-2 inhibition at tested concentrations.TradingViewMIRA Pharmaceuticals Reports Weight and Fat Reduction With Oral SKNY-1 in Obese MiceMIRA Pharmaceuticals reported that oral SKNY-1 significantly reduced body weight and fat mass in obese mice, with favorable lean-mass and weight-regain findings versus semaglutide. Weight reduction occurred without a statistically significant decrease in food consumption, and SKNY-1-treated mice showed slow, limited weight regain after treatment stopped. MIRA plans further preclinical studies, including direct investigation of energy expenditure and other metabolic parameters.Business & FinancialCannabinoid Agonist Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead The Charge In Pioneering New Treatments DelveinsightDelveInsight's report on the cannabinoid agonist pipeline covers 20+ companies and 22+ pipeline drugs. MIRA Pharmaceuticals reported positive preclinical results for MIRA-55 in chronic pain, and Endovia Health Sciences and Lupvindol BioSciences advanced CannEpil toward a conditional approval pathway. The report also profiles other companies and therapies in the space.TradingViewMIRA Pharmaceuticals Reports MIRA-55 Pain Relief Comparable to Celebrex in Preclinical StudyMIRA Pharmaceuticals reported that oral MIRA-55 reduced chronic inflammatory pain in a 21-day preclinical study, with effects comparable to celecoxib. The drug reduced mechanical and thermal pain hypersensitivity, inflammation-associated paw swelling, and showed no tolerance or adverse signs. MIRA is advancing MIRA-55 toward a planned IND submission in Q1 2027.Markets DailyMIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Stock Short Interest Jumps 118.1%Short interest in MIRA Pharmaceuticals surged 118.1% to 447,832 shares as of September 15th, with 1.3% of shares short sold. The stock traded down $0.03 to $0.87, and analysts have a consensus "Hold" rating with a $3.50 price target.BioSpaceMIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA ReviewMIRA Pharmaceuticals submitted its Phase 2a protocol for Ketamir-2 in chemotherapy-induced peripheral neuropathy (CIPN) for IRB review after FDA feedback. The randomized, double-blind, placebo-controlled study will enroll adults with moderate-to-severe persistent CIPN, with site initiation targeted in Q1 2027. The company expects to present results at the International Conference on Addiction and Psychiatry in Tokyo in October 2026.BioSpaceMIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward INDMIRA Pharmaceuticals reported positive toxicology results from 7-day rat and dog studies of its oral non-opioid pain drug MIRA-55, informing dose selection. The company plans to use these findings for subsequent GLP toxicology studies and targets an FDA IND submission in Q1 2027.Markets DailyMIRA Pharmaceuticals (NASDAQ:MIRA) Releases Earnings ResultsMIRA Pharmaceuticals reported a quarterly earnings loss of $0.03 per share on Wednesday. The company's stock price rose to $0.78 during midday trading, while Weiss Ratings upgraded its rating from 'sell (e+)' to 'sell (d-)'.GlobeNewswireMIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling StudiesMIRA Pharmaceuticals advanced its lead programs MIRA-55 and SKNY-1 through formulation, CMC, manufacturing, and exploratory toxicology studies. The company completed non-GLP repeated-dose toxicology and toxicokinetic studies in rats and dogs, supporting future GLP studies. These milestones strengthen the development packages for both candidates.FinancialContent Business PageMIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory PainMIRA Pharmaceuticals announced positive results from preclinical pharmacokinetic studies evaluating an optimized oral formulation of MIRA-55, a non-opioid drug candidate for chronic inflammatory pain. The selected lead formulation demonstrated favorable oral bioavailability with sustained systemic exposure and reproducible distribution into both brain and liver tissue following oral administration. The company plans to continue advancing MIRA-55 through additional preclinical development, building on prior efficacy data showing the candidate outperformed injected morphine in an inflammatory pain model.